6266-66-6Relevant academic research and scientific papers
Agent for Preventing or Ameliorating Hearing Impairment
-
Paragraph 0093; 0094; 0185-0186, (2019/08/02)
It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.
INDOLE-ACETIC ACID-AMIDO DERIVATIVE
-
Paragraph 0104; 0105; 0106, (2018/09/25)
PROBLEM TO BE SOLVED: To provide a compound useful as a therapeutic and/or preventive agent for a disease associated with an abnormality in mitochondrial functions. SOLUTION: The present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof [Xa-Xd independently represent H, a halogen atom, a trifluoromethyl group, a phenyl group or a cyclohexyl group; Z is H, a methyl group, a cyclohexyl group or F, or a phenyl group optionally substituted with a methoxy group; A is a C4-6 alkyl group substituted with 3-5 F atoms, a difluorocyclohexyl-ethyl group, or a methylene group, a methylene carbonyl group or an oxyethylene group having a substituted/unsubstituted phenyl group at a terminal]. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT
Erythropoietin Expression Promoter
-
Paragraph 0207; 0208, (2015/12/30)
The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.
